A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer

Phase 3 Terminated 31 enrolled Suzhou Suncadia Biopharmaceuticals Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is being conducted to evaluate the efficacy, and safety of SHR-1701 or Placebo Plus Chemotherapy With or Without BP102 (Bevacizumab) as First-Line Treatment in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer.

Timeline

Start: 2022-02-26
Primary completion: 2024-08-12
Completion: 2024-08-12

Outcome

Outcome not reported

Stopped (Business): “Sponsor develops strategy adjustment”

Publications

Feng J, Tang D, Wang J, Zhou Q, Peng J, Lou H, Sun Y, Cai Y, Chen H, Yang J, Liu P, Wang L, Zou J. SHR-1701, a Bifunctional Fusion Protein Targeting PD-L1 and TGFbeta, for Recurrent or Metastatic Cervical Cancer: A Clinical Expansion Cohort of a Phase I Study. Clin Cancer Res. 2022 Dec 15;28(24):5297-5305. doi: 10.1158/1078-0432.CCR-22-0346.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	BP102	Monoclonal antibody	—	—
Subject	Retlirafusp alfa	Protein / enzyme biologic	—	—
Comparator	Carboplatin	Small molecule	—	—
Comparator	Cisplatin	Other / unclassified	—	—
Comparator	Paclitaxel	Small molecule	—	—